Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We hope the weekend break was something of a respite from the dizzying pace of concerning events occurring beyond your front door. Nonetheless, the world keeps spinning and here we are, once again, at the dawn of another working week. On that note, we are firing up the coffee kettle and searching for items of interest. We hope your day is manageable and productive. Meanwhile, here are some tidbits. Stay safe, everyone.

A team of researchers reported that nearly 70 drugs and experimental compounds may be effective in treating the coronavirus, The New York Times writes. Some of the medications are already used to treat other diseases, and repurposing them to treat Covid-19, the illness caused by the coronavirus, may be faster than trying to invent a new antiviral from scratch. The list of drug candidates appeared in a study published on the website bioRxiv and the researchers have submitted the paper to a journal for publication.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.